Adaptimmune Therapeutics Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Adaptimmune Therapeutics Plc (ADAP) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Adaptimmune Therapeutics Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 65M vs 83,750M combined for tracked competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-15.9% annualized vs trailing 12 months), vs decelerating (-17.0%) for its tracked peer group.
- Growth: Adaptimmune Therapeutics Plc generated -89.3% revenue growth year over year in Q2 2025, vs 4.9% for its tracked competitors combined.
- Profitability: Its -221.8% net margin compares with 12.5% for the peer group.
- Peer revenue share: Adaptimmune Therapeutics Plc accounted for 0.1% of combined revenue among its tracked peer group, down from 0.8% a year earlier.
- Peer differentiation: Revenue per employee of $0.26M compares with $1.91M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ADAP Sales vs. its Competitors, Q2 2025
Adaptimmune Therapeutics Plc reported revenue contraction of 89.33 % year on year in Q2 2025, below its competitors' combined revenue growth of 4.94 %.
With a net margin of -221.83 %, Adaptimmune Therapeutics Plc reported lower profitability than its competitors (12.49 %).
Adaptimmune Therapeutics Plc generated 0.08 % of the combined sales of its peer group, down from 0.77 % a year earlier.
Adaptimmune Therapeutics Plc vs. its Competitors, Q2 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Adaptimmune Therapeutics Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Adaptimmune Therapeutics Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (12) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Adaptimmune Therapeutics Plc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs -89.3% for Adaptimmune Therapeutics Plc. Adaptimmune Therapeutics Plc's share of combined industry revenue moved from 0.35% to 0.03%, a loss of 0.32 percentage points.
Adaptimmune Therapeutics Plc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Adaptimmune Therapeutics Plc | No | No | No | Yes |
| Competitors combined (55) | ||||
| High-Confidence Competitors (14) | ||||
| Similar Growth & Profitability (8) | 12.50 % (1 of 8) | 25.00 % (2 of 8) | 0.00 % (0 of 8) | 62.50 % (5 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ADAP Stock Performance relative to its Competitors
ADAP Stock Performance relative to High-Confidence Competitors
ADAP Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Century Therapeutics inc | 282.9% | Outperformed |
| 3 | Inhibrx Biosciences Inc | 282.9% | Outperformed |
| 4 | Replimune Group Inc | 282.9% | Outperformed |
| 5 | Fate Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Adaptimmune Therapeutics Plc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Adaptimmune Therapeutics Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Adaptimmune Therapeutics Plc | 14.50 | 65.09 |
| Amgen Inc | 227,462.72 | 38,095.00 |
| Gilead Sciences Inc | 189,197.03 | 30,457.00 |
| Moderna Inc | 78,517.44 | 2,228.00 |
| Argenx Se | 64,196.90 | 8,399.37 |
| Exelixis Inc | 15,157.23 | 2,435.92 |
| SUBTOTAL | 590,829.82 | 84,178.90 |
Sign in to see all competitors of Adaptimmune Therapeutics Plc.
Sources: Adaptimmune Therapeutics Plc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Adaptimmune Therapeutics Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Adaptimmune Therapeutics Plc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Phoenix Biotech Acquisition Corp | Named by the company | 85% |
| Cue Biopharma Inc | Named by the company | 85% |
| Lunai Bioworks Inc | Named by the company | 85% |
| Instil Bio Inc | Named by the company | 85% |
| CARVYTKI TM | Named by the company | 85% |
| Yescarta TM | Named by the company | 85% |
| Immunocore Holdings Plc | Named by the company | 85% |
| RENB | Named by the company | 85% |
| Allogene Therapeutics | Named by the company | 85% |
| Takeda Pharmaceuticals Limited | Named by the company | 85% |
| Samsara Luggage Inc | Named by the company | 85% |
| Marker Therapeutics inc | Named by the company | 85% |
| Fate Therapeutics Inc. | Named by the company | 85% |
| Iovance Biotherapeutics inc | Named by the company | 85% |
| Tscan Therapeutics Inc | Named by the company | 85% |
| Breyanzi TM | Named by the company | 85% |
| Tecartus TM | Named by the company | 85% |
| Tradeup Acquisition Corp | Named by the company | 85% |
| Abecma TM | Named by the company | 85% |
| Kymria TM | Named by the company | 85% |
| Celularity Inc | Named by the company | 85% |
| Neximmune Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Adaptimmune Therapeutics Plc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Adaptimmune Therapeutics Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Exelixis Inc | Reportable 100.00 % |
| Immunocore Holdings Plc | Reportable 100.00 % |
| Autolus Therapeutics Plc | Reportable 100.00 % |
| Century Therapeutics inc | Single reportable segment 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Adaptimmune Therapeutics Plc.
Adaptimmune Therapeutics Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Adaptimmune Therapeutics Plc | 14 | 264,573 | -690,065 |
| Amgen Inc | 227,463 | 2,930,385 | 672,538 |
| Gilead Sciences Inc | 189,197 | 1,791,588 | -190,588 |
| Moderna Inc | 78,517 | 474,043 | -670,426 |
| Argenx Se | 64,197 | 7,316,521 | 1,125,466 |
| Exelixis Inc | 15,157 | 2,123,731 | 1,653,085 |
| PEERS TOTAL | 590,815 | 1,911,634 | 59,897 |
Sign in to see all peers for Adaptimmune Therapeutics Plc.
Adaptimmune Therapeutics Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 70.78 % |
| Exelixis Inc | United States 91.44 % |
| Novocure Limited | United States 56.08 % |
| Agenus Inc | US 100.00 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Adaptimmune Therapeutics Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Adaptimmune Therapeutics Plc's industry classification, broader than the peer set above. Market cap in millions of $.Adaptimmune Therapeutics Plc ranks #0 of 159 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,331, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 226,707 | 26.02 % |
| 2 | Gilead Sciences Inc | 185,928 | 21.34 % |
| 3 | Moderna Inc | 76,517 | 8.78 % |
| 4 | Argenx Se | 63,326 | 7.27 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 0 | Adaptimmune Therapeutics Plc | 87 | 0.00 % |
Market cap and industry share for the rest of Adaptimmune Therapeutics Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-10-27.
Adaptimmune Therapeutics Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (93 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 90.52 % | 68.46 % (avg) | +22.1 pp |
| Operating Margin | -252.32 % | industry median | -82.3 pp |
| EBITDA Margin | -238.79 % | -0.94 % (avg) | -237.9 pp |
| Capital Intensity (Capex / Revenue) | 3.07 % | 6.74 % (avg) | -3.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Adaptimmune Therapeutics Plc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | - | 21.3x | - |
| P/B | -16.7x | 5.1x | -21.8x |
| Return on Equity | 4,103.11 % | industry aggregate | 4,093.38 % |
| Return on Invested Capital | -105.88 % | -6.17 % (avg) | -99.71 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Adaptimmune Therapeutics Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 166.47 % | 57.28 % | -164.18 % | - | 209.86 % | 190.80 % | 110.11 % | 195.34 % |
| Operating Margin | -213.20 % | -138.42 % | 365.98 % | -2,127.33 % | -1,661.10 % | -571.51 % | -231.82 % | -38.62 % |
| Return on Invested Capital | -17.95 % | -18.55 % | -38.44 % | -18.42 % | -24.44 % | -38.60 % | -39.26 % | -25.26 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Adaptimmune Therapeutics Plc's Strategic Group Map
Every company in Adaptimmune Therapeutics Plc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Adaptimmune Therapeutics Plc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Adaptimmune Therapeutics Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,331 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 3.07 % vs industry average 6.74 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Adaptimmune Therapeutics Plc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Adaptimmune Therapeutics Plc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Adaptimmune Therapeutics Plc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Adaptimmune Therapeutics Plc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Adaptimmune Therapeutics Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 4,093.4 points above the industry aggregate.
Weaknesses
- Operating margin 82.3 points below the industry median.
- Latest-quarter revenue run-rate is decelerating (-15.9% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (51.90 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-17.0% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Adaptimmune Therapeutics Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Adaptimmune Therapeutics Plc | 1.19 | 2.66 | - |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Argenx Se | 2.64 | 5.23 | - |
| Exelixis Inc | 0.90 | 3.51 | - |
Sign in to see all peers for Adaptimmune Therapeutics Plc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Adaptimmune Therapeutics Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Adaptimmune Therapeutics Plc | Q2 2025 | -89.3 % | - |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Argenx Se | Q4 2025 | +89.1 % | +55.1 % |
| Exelixis Inc | Q2 2026 | +10.6 % | +14.3 % |
| PEERS TOTAL | +27.1 % | - |
Sign in to see all peers for Adaptimmune Therapeutics Plc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Adaptimmune Therapeutics Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Adaptimmune Therapeutics Plc | Q2 2025 | - | -91.2 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Argenx Se | Q4 2025 | +44.6 % | +242.3 % |
| Exelixis Inc | Q2 2026 | +6.1 % | +140.2 % |
Sign in to see all peers for Adaptimmune Therapeutics Plc.
Adaptimmune Therapeutics Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Adaptimmune Therapeutics Plc | - | - | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Gilead Sciences Inc | - | - | - |
| Moderna Inc | - | - | - |
| Argenx Se | 14.88% | 14.81% | 17.64% |
| Exelixis Inc | 70.51% | 82.05% | 93.62% |
Sign in to see all peers for Adaptimmune Therapeutics Plc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Adaptimmune Therapeutics Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Adaptimmune Therapeutics Plc | - | 0.22 |
| Amgen Inc | 25.97 | 5.97 |
| Gilead Sciences Inc | - | 6.21 |
| Moderna Inc | - | 35.24 |
| Argenx Se | 49.68 | 7.64 |
| Exelixis Inc | 18.41 | 6.22 |
| PEERS AVERAGE | 239.61 | 7.02 |
Sign in to see all peers for Adaptimmune Therapeutics Plc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.